Percutaneous Coronary Intervention Rates and Associated Independent Predictors for Progression of Nontarget Lesions in Patients With Diabetes Mellitus After Drug-Eluting Stent Implantation
Restricted accessResearch articleFirst published online January, 2016
Percutaneous Coronary Intervention Rates and Associated Independent Predictors for Progression of Nontarget Lesions in Patients With Diabetes Mellitus After Drug-Eluting Stent Implantation
Little is known about clinically driven percutaneous coronary intervention (PCI) rates and predictors for progression of nontarget lesions in diabetic patients who have undergone drug-eluting stent (DES) implantation. We retrospectively analyzed the clinical and angiographic data of 2187 diabetic patients undergoing DES implantation. The cumulative rate of nontarget lesion PCI was 6.3% at 1 year, 14.3% at 2 years, and 19.8% at 3 years. The independent predictors of need for clinically driven PCI in patients with diabetes mellitus after DES implantation included obesity (odds ratio [OR] 2.303, 95% confidence interval [CI] 1.657-3.199, P < .001), low levels of high-density lipoprotein cholesterol (OR 1.412, 95% CI 1.114-1.789, P = .004), statin use (OR 0.669, 95% CI 0.454-0.986, P = .042), insulin use (OR 1.310, 95% CI 1.030-1.665, P = .027), and Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (OR 1.061, 95% CI 1.045-1.077, P < .001) at baseline PCI. These findings may facilitate prediction of the risk of repeat revascularization and improve repeat revascularization rates in diabetic patients after DES implantation.
NorhammarAMalmbergKDiderholmE. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43(4):585–591.
2.
PfistererMEZellwegerMJGershBJ. Management of stable coronary artery disease. Lancet. 2010;375(9716):763–772.
3.
LoutfiMMulvihillNTBoccalatteMFarahBFajadetJMarcoJ. Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients. Catheter Cardiovasc Interv. 2003;58(4):451–454.
4.
TousekPPaveiAOregliaJ. Impact of atherosclerotic disease progression on mid-term clinical outcome in diabetic patients in the drug-eluting stent era. EuroIntervention. 2009;4(5):588–592.
5.
KedhiEGenereuxPPalmeriniT. Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. J Am Coll Cardiol. 2014;63(20):2111–2118.
6.
MarsoSPMercadoNMaeharaA. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging. 2012;5(3 suppl):S42–S52.
7.
BoylePJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med. 2007;120(9 suppl 2):S12–S17.
8.
LeveyASCoreshJGreeneT. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254.
9.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–266.
10.
Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.
11.
Guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on coronary angiography). J Am Coll Cardiol. 1987;10(4):935–950.
12.
SianosGMorelMAKappeteinAP. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219–227.
13.
SerruysPWOnumaYGargS. Assessment of the SYNTAX score in the Syntax study. EuroIntervention. 2009;5(1):50–56.
14.
ParkMWSeungKBKimPJ. Long-term percutaneous coronary intervention rates and associated independent predictors for progression of nonintervened nonculprit coronary lesions. Am J Cardiol. 2009;104(5):648–652.
15.
YinZXZhouYJLiuXLHanHYYangSW. Clinical predictors for progression of nonintervened nonculprit coronary lesions despite low-density lipoprotein cholesterol less than 1.8 mmol/l after successful stent implantation. Coron Artery Dis. 2011;22(1):49–54.
16.
NichollsSJTuzcuEMKalidindiS. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52(4):255–262.
17.
KanekoHYajimaJOikawaY. Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention. Heart Vessels. 2014;29(4):437–442.
18.
MatsudaMShimomuraI. Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract. 2013;7(5): e330–341.
19.
YudkinJSKumariMHumphriesSEMohamed-AliV. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?Atherosclerosis. 2000;148(2):209–214.
20.
SchneiderDJHardisonRMLopesNSobelBEBrooksMM; Pro-Thrombosis Ancillary Study G. Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. Diabetes Care. 2009;32(5):944–949.
21.
YudkinJSStehouwerCDEmeisJJCoppackSW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?Arterioscler Thromb Vasc Biol. 1999;19(4):972–978.
22.
McGillHCJrMcMahanCAHerderickEE. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105(23):2712–2718.
23.
CalleEEThunMJPetrelliJMRodriguezCHeathCWJr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097–1105.
24.
WeeCCGirotraSWeinsteinARMittlemanMAMukamalKJ. The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy. J Am Coll Cardiol. 2008;52(8):620–625.
25.
WangZJZhouYJZhaoYX. Effect of obesity on repeat revascularization in patients undergoing percutaneous coronary intervention with drug-eluting stents. Obesity (Silver Spring). 2012;20(1):141–146.
26.
BayturanOKapadiaSNichollsSJ. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55(24):2736–2742.
27.
GrantRWMeigsJB. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care. 2007;30(3):479–484.
28.
MorgantiniCMeriwetherDBaldiS. HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis. 2014;24(6):594–599.
29.
NicholsGAVupputuriSRosalesAG. Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. Am J Cardiol. 2011;108(8):1124–1128.
30.
OgitaMMiyauchiKMiyazakiT. Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart Vessels. 2014;29(1):35–41.
31.
RiwantoMRohrerLvon EckardsteinALandmesserU. Dysfunctional HDL: From Structure-Function-Relationships to Biomarkers. Handb Exp Pharmacol. 2015;224:337–366.
32.
Otocka-KmiecikAMikhailidisDPNichollsSJDavidsonMRyszJBanachM. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?Prog Lipid Res. 2012;51(4):314–324.
33.
BergenstalRM. Optimization of insulin therapy in patients with type 2 diabetes. Endocr Pract. 2000;6(1):93–97.
34.
StankovicGCosgraveJChieffoA. Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol. 2006;98(3):362–366.
35.
ParkDWFlahertyJDDavidsonCJ. Prognostic influence of diabetes mellitus on long-term clinical outcomes and stent thrombosis after drug-eluting stent implantation in Asian patients. Am J Cardiol. 2009;103(5):646–652.
36.
HoebersLPClaessenBEWoudstraP. Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention. 2014;10(1):90–96.
37.
KaplanMAviramMHayekT. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy. Pharmacol Ther. 2012;136(2):175–185.
38.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.
39.
ChaudhryZWGannonMCNuttallFQ. Stability of body weight in type 2 diabetes. Diabetes Care. 2006;29(3):493–497.
40.
LargerE. Weight gain and insulin treatment. Diabetes Metab. 2005;31(4 pt 2):4S51–54S56.
41.
AngiolilloDJBernardoERamirezC. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48(2):298–304.
42.
WykrzykowskaJJGargSGirasisC. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol. 2010;56(4):272–277.
43.
MagroMNautaSSimsekC. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: The MI SYNTAXscore study. Am Heart J. 2011;161(4):771–781.
44.
SerruysPWOnumaYGargS. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010;55(11):1093–1101.
45.
PalmeriniTGenereuxPCaixetaA. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. J Am Coll Cardiol. 2011;57(24):2389–2397.
46.
YangCHHsiehMJChenCC. The prognostic significance of SYNTAX score after early percutaneous transluminal coronary angioplasty for acute ST elevation myocardial infarction. Heart Lung Circ. 2013;22(5):341–345.
47.
ValgimigliMSerruysPWTsuchidaKVainaSMorelMAvan den BrandMJ. Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol. 2007;99(8):1072–1081.
48.
CapodannoDDi SalvoMECincottaGMianoMTamburinoCTamburinoC. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease. Circ Cardiovasc Interv. 2009;2(4):302–308.
49.
GargSSarnoGSerruysPW. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials. JACC Cardiovasc Interv. 2011;4(1):66–75.
50.
TaniwakiMStefaniniGGSilberS. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014;63(16):1617–1625.
51.
ColhounHMBetteridgeDJDurringtonPNHitmanGANeilHALivingstoneSJ. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696.
52.
SeverPSPoulterNRDahlofB. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28(5):1151–1157.
53.
KnoppRHd’EmdenMSmildeJGPocockSJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29(7):1478–1485.
54.
TajimaNKurataHNakayaN. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis. 2008;199(2):455–462.
55.
KataokaYYasudaSMiyamotoY. Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: Insight from the DIANA study. J Atheroscler Thromb. 2014;21(5):509–518.
56.
ShepherdJBarterPCarmenaR. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29(6):1220–1226.
57.
LemesleGBonelloLde LabriolleA. Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol. 2009;104(1):41–45.
58.
Action to Control Cardiovascular Risk in Diabetes Study G; GersteinHCMillerMEByingtonRP. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
59.
MellbinLGMalmbergKNorhammarAWedelHRydenL; DIGAMI 2 Investigators. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J. 2008;29(2):166–176.
60.
UedaHMitsusadaNHarimotoKMiyawakiMYasugaYHiraokaH. Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantation in patients with diabetes mellitus. Cardiology. 2010;116(1):51–57.
61.
KassaianSEGoodarzynejadHBoroumandMA. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol. 2012;11:82.
62.
HaraHAokiJTanabeK. Incidence and predictors for late target lesion revascularization after sirolimus-eluting stent implantation. Circ J. 2013;77(4):988–994.
